A compelling clinical conversation with Dr. Lisa Christopher-Stine, Director of Johns Hopkins Myositis Center, on recognizing, diagnosing, and treating immune-mediated necrotizing myopathy - an often-overlooked statin-related condition.
Werfen recently partnered with the National Lipid Association on a special podcast episode of the Industry Innovations series focused on statin-associated autoimmune myopathy. In this episode, Dr. Lisa Christopher-Stine joins host Dr. Alan Brown to explore the rare but serious condition of statin-associated autoimmune myopathy.
Learn how HMGCR antibody testing plays a pivotal role in distinguishing statin-associated autoimmune myopathy from more common statin-related muscle symptoms. In many cases, it can provide diagnostic clarity without the need for invasive muscle biopsy.
Whether you're a lipidologist, rheumatologist, or primary care provider, this podcast episode offers essential insights into a condition that may already be presenting in your patients—but is often difficult to recognize and differentiate.
Explore autoimmune statin-induced myopathy, how it differs from toxic statin myopathy, and the key muscle biopsy findings and immune markers that define it, along with the condition’s evolving history and terminology.
This chapter presents a detailed case of a male with diabetes and coronary disease, reviewing his symptoms, disease progression, and the diagnostic steps taken. It also highlights the classic phenotype and associated risk factors, including atorvastatin use and diabetes.
Explore the discovery of HMGCR antibodies in statin-naive patients and discuss the environmental and genetic factors that may contribute. We also examine differences in presentation and biopsy findings, as well as global variation in statin exposure.
The conversation shifts to distinguishing common statin-related muscle symptoms from autoimmune myopathy. While typical myalgias resolve quickly after stopping statins, autoimmune cases present with high CPK levels and progressive weakness, requiring early recognition and intervention to prevent irreversible muscle damage.
This chapter explores diagnostic strategies, emphasizing the specificity of HMGCR antibody testing over muscle biopsy. Dr. Christopher-Stine and Dr. Brown compare autoimmune and toxic statin myopathies, discuss symptom onset timelines, and note atorvastatin’s strong association with autoimmune cases, including features like dysphagia.
The segment highlights the challenges of managing patients with comorbidities, such as diabetes, and the cautious use of PCSK9 inhibitors for lipid control. Differences in treatment response between statin-naive and statin-associated cases are also explored.
This chapter emphasizes the importance of specialist referral, whether to rheumatology or neurology, reviews long-term immunotherapy considerations, highlights collaborative care models, and offers final thoughts and key takeaways for lipidologists.